BioTuesdays

Category - Markets

Vera-Therapeutics
Markets

HCW starts Vera Therapeutics at buy; PT $35

H.C. Wainwright launched coverage of Vera Therapeutics (NASDAQ:VERA) with a “buy” rating and $35 price target. The stock closed at $20 on April 29. Vera is a clinical-stage biotech company focused on developing disease...

May 2, 2022
acutus logo
Markets

BTIG ups Acutus Medical to buy; PT $2

BTIG upgraded Acutus Medical (NASDAQ:AFIB) to “buy” from “neutral” with a price target of $2, after the company announced a debt refinancing and the sale of its left-heart access product portfolio that should extend its...

April 27, 2022
Opthea-Logo
Markets

SVB starts Opthea at OP; PT $25

SVB Securities launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $25 price target. The stock closed at $5.71 on April 25. Opthea is a clinical-stage biotechnology company focused on developing...

April 26, 2022
Markets

Maxim starts Processa Pharma at buy; PT $9

Maxim Group initiated coverage of Processa Pharmaceuticals (NASDAQ:PCSA) with a “buy” rating and $9 price target. The stock closed at $2.87 on April 18. Processa is a clinical-stage company developing therapies for...

April 19, 2022
AN2 Theraputics
Markets

SVB Leerink starts AN2 Therapeutics at OP; PT $27

SVB Leerink launched coverage of AN2 Therapeutics (NASDAQ:ANTX) with an “outperform” rating and price target of $27. The stock closed at $14.79 on April 18.   AN2 is a clinical-stage biotech company developing therapies...

April 19, 2022
Biodesix Logo
Markets

BTIG ups Biodesix PT to $17 from $10

BTIG raised its price target for Biodesix (NASDAQ:BDSX) to $17 from $10, saying “performance this year should restore investor confidence.” The stock closed at $1.61 on April 14. Analyst Sung Ji Nam writes that the...

April 15, 2022
Graphite Bio
Markets

BTIG starts Graphite Bio at buy; PT $18

BTIG initiated coverage of Graphite Bio (NASDAQ:GRPH) with a “buy” rating and price target of $18. The stock closed at $4.15 on April 13. “We believe Graphite Bio’s homology directed repair technology platform...

April 14, 2022
Alpha Tau
Markets

Cantor starts Alpha Tau Medical at OW; PT $20

Cantor Fitzgerald launched coverage of Alpha Tau Medical (NASADQ:DRTS) with an “overweight” rating and $20 price target. The stock closed at $10.58 on April 13. Alpha Tau, which went public in March 2022, is a medical...

April 14, 2022
Synaptogenix
Markets

Maxim starts Synaptogenix at buy; PT $14

Maxim Group launched coverage of Synaptogenix (NASDAQ:SNPX) with a “buy” rating and price target of $14. The stock closed at $7.03 on April 11. Synaptogenix, formerly Neurotrope, is continuing development of bryostatin...

April 12, 2022